Search PubMed⌕ Search

Biomedical subjects

J Markowska

Publications and source records attributed to J Markowska.

At least 55 records · Page 3Linked to original sources
PubMed1992

[Role of second-look operations in women with ovarian cancer in complete remission].

Among 142 women with ovarian cancer, a complete remission was observed in 51 cases. The second-look operation was performed in 26 cases among them. The operation had no significant influence on 3 and 5 years survivals together. The operation should not be performed in early stages of cancer particularly in mucinous and endometrioid carcinoma. Relapses are observed more frequently and in a shorter period of time in women on whom the second-look operation was not performed. Then it leads to deaths of the women more quickly.

Adult↗
PubMed1992

Phenotype of lymphocyte in ovarian tumor peritoneal fluid. A preliminary study.

Phenotype of lymphocytes was estimated in 16 peritoneal fluids obtained from 9 ovarian cancer patients. Peritoneal fluids contained predominantly T cells (more than 80%) while B cell content was relatively low. Approximately 50% lymphocytes carried T-helper cell marker (CD4). Percentage of T-cytotoxic/suppressor cells (CD8+ cells) differed between patients with progression and those showing no tumor progression (19.0 +/- 7.5 vs 32.7 +/- 18.5). CD4/CD8 ratio was higher in the group of patients with progression than in the group with no progression of the tumor (3.4 +/- 2.1 and 2.0 +/- 1.5). Chemotherapy did not affect the parameters. Estimation of CD8 and CD4/CD8 ratio in peritoneal fluid cells could be helpful in monitoring of disease progression.

Adult↗
PubMed1992

Value of CA 125 as a marker of ovarian cancer.

Elevated CA 125 level was noted in 0.2-5.9% healthy women, 2.2-27.8% patients with benign ovarian cysts, and approximately 80% patients with nonmucinous ovarian cancer. In the early stages of cancer, CA 125 level was lower than in the disseminated process (with tendency to higher levels in cases of accompanying exudates to body cavities). The level was found to correlate with the mass of tumor, extent of surgery and response to chemotherapy. Maintenance or increase in CA 125 level after three months of chemotherapy was found to indicate ineffectiveness of the treatment, suggesting a more aggressive therapeutic strategy. The estimation of CA 125 half life after the first two courses of chemotherapy was noted to be a good prognostic factor (9.2 to 10.73 days in patients with total remission, and 22.6 to 44.87 days in patients with progression). The monitoring of ovarian cancer courses using CA 125 level estimations in the serum facilitated decisions at to the timing of the second-look operation; elevated level of the marker was found to indicate that the latter was superfluous. Elevated CA 125 level proceeded clinical diagnosis of relapse by 3 to 6 months, but only in the patients who at earlier stages of the treatment also showed abnormal levels of the marker. The monitoring of patients with complete remission who showed normal CA 125 level throughout the treatment was found useless.

Antigens, Tumor-Associated, Carbohydrate↗
PubMed1992

Dystrophy of the vulva locally treated with 13-cis retinoic acid.

Topical application of 13-cis retinoic acid resulted in complete disappearance of dystrophy of the vulva in 33 out of 53 patients, among them in 9 patients with recurrence after vulvectomy and in 14 patients with previous unsuccessful conservative treatment. Partial disappearance of dystrophy was seen in 15 patients, usually after 1 to 2 months of daily retinoid treatment. Side-effects of treatment (except for one) could be managed. Serum retinol level in patients was found to be lower as compared to that in healthy subjects. The results suggest that patients with chronic epithelial vulvar dystrophies could benefit from local retinol treatment, especially in cases with recurrence after vulvectomy and in cases with advanced dystrophies qualified until now for vulvectomy.

Administration, Topical↗
PubMed1992

CA 125 in monitoring clinical course in ovarian cancer patients. A prospective clinical study.

CA 125 concentration was estimated using an immunoenzymatic test (Abbott) in sera of 130 women treated for ovarian cancer, before the treatment was started and during chemotherapy. Serum half-life of CA 125 was estimated in several of the patients after three months of chemotherapy. CA 125 serum level was found to be associated with the clinical course. Before the treatment was started, CA 125 levels showed no prognostic value as to survival but absence of a decrease in CA 125 levels after 2 to 3 months of chemotherapy was unfavourable to survival and required that alteration in treatment scheme be considered. Estimation of CA 125 half-life time after three months of treatment provided a useful prognostic index. Monitoring with the use of CA 125 levels facilitated adequate decision as to the time of performing second-look surgery. In patients with CR, who showed normal CA 125 levels at earlier stages of treatment, monitoring with the use of the marker was useless, since no elevation of CA 125 level was observed during relapse.

Adult↗
PubMed1990

CA 125 in monitoring chemotherapy of the patients with ovarian cancer.

Changes in CA 125 antigen concentration and serum half-life were determined in 63 women with ovarian carcinoma during chemotherapy following various types of surgery. Concentration of CA 125 in serum correlated with the degree of clinical advancement of the tumor, 20.00 and 688.84 U per ml at stages I, II, and IV, respectively, and with remaining tumor mass, despite chemotherapy, serum CA 125 level rose after exploratory surgery. Estimation of CA 125 levels proved less useful in the mucinous type of ovarian carcinoma. The treatment scheme including Cisplatinum reduced CA 125 levels most effectively correlated with good clinical response to the therapy. Testing the half-life time appeared to provide a good prognostic index, 6.25 +/- 2.08 days after radical surgery and 44.87 +/- 26.5 days after probatory laparotomy.

Antigens, Tumor-Associated, Carbohydrate↗
PubMed1990

CA 125 in monitoring chemotherapy of patients with ovarian cancer: early response to the treatment.

Using an immunoenzymatic technique, changes in serum levels of CA 125 were examined in 63 patients with ovarian carcinoma before treatment as well as following the first four courses of chemotherapy. Serum CA 125 level before treatment was dependent upon clinical advancement stage (20.0, 393.43 and 688.84 U/ml at the Stages I + II, III and IV, respectively). Good response to treatment was associated with decreased CA 125 levels, while tumor progression was linked to increasing levels of the marker. Treatment scheme including cisplatinum induced most pronounced decrease in serum CA 125 level which paralleled good clinical response to the treatment. Determination of CA 125 half-life time in serum seemed to provide a sensitive prognostic index in the disease. This index amounted to 10.73 +/- 4.0 days in patients with complete remission and 44.87 +/- 26.5 days in patients with progressive disease.

Antigens, Tumor-Associated, Carbohydrate↗
PubMed1987

Leukoplakia of the vulva locally treated by 13-cis-retinoic acid.

Repeated topical application of 13-cis-retinoic acid resulted in complete disappearance of leukoplakia of the vulva in 8 out of 16 patients, among them 2 out of 3 with recurrence after vulvectomy. A considerable regression of leukoplakia was seen in 7 other patients, usually after 1 to 2 months of daily retinoid treatment. After 2-4 months of maintenance therapy and during 3-7 months of the follow up period no recurrences were seen. Side effects of treatment could be managed. Serum retinol level was found to be lower in patients then in healthy subjects. The results suggest that patients with chronic epithelial vulvar dystrophies could benefit from local retinoid treatment, especially in cases with advanced dystrophies until now qualified for vulvectomy.

Administration, Topical↗
PubMed1986

PHA responsiveness and adherent cell-lymphocyte interactions in patients with advanced malignant tumors of the ovary prior to treatment and during chemotherapy.

DNA synthesis in cultures of PHA-stimulated blood mononuclear cells from patients with advanced malignant tumors of the ovary before treatment was significantly reduced and responses of lymphocytes alone were, on an average, 40% lower than in control subjects. Adherent cells were found to suppress the PHA response of autologous lymphocytes from 6/12 patients before treatment, 4/18 patients during chemotherapy and only in 2/19 control subjects. The net effects of adherent cell-lymphocyte interactions in autogeneic vs. allogeneic combinations were frequently discordant, which suggests shifts in lymphocyte subpopulations responsive, respectively, to suppressor- and helper-type mediators released by monocytes in patients. PHA responses of mononuclear blood cells from patients after the 1st and 2nd round of chemotherapy were usually higher than the mean in untreated patients, but declined rapidly after subsequent rounds of cytostatic drug treatment and were deeply impaired in a few cured patients examined many months after therapy. Previous radiotherapy appeared to have little effect on the magnitude and patterns of changes of blood mononuclear response to PHA during subsequent chemotherapy.

Adult↗